Opler L A, Feinberg S S
Department of Psychiatry, College of Physicians & Surgeons, Columbia University, New York, N.Y.
J Clin Psychiatry. 1991 May;52(5):221-33.
Pimozide, a diphenylbutylpiperidine neuroleptic which is FDA-approved as a backup treatment for Gilles de la Tourette's syndrome, has been used abroad for many years as a treatment of schizophrenia and has been recently reported to be particularly effective in treating monosymptomatic hypochondriacal psychosis and delusional jealousy. Pimozide may also have a role in the treatment of negative schizophrenic symptoms, pain syndromes, and obsessive compulsive disorder. After reviewing the relevant clinical literature supporting these indications, the authors review preclinical studies that provide points of departure regarding biochemical mechanisms underlying this unique therapeutic profile.
匹莫齐特是一种二苯基丁基哌啶类抗精神病药物,被美国食品药品监督管理局(FDA)批准作为抽动秽语综合征的二线治疗药物,在国外已被用于治疗精神分裂症多年,最近有报道称其在治疗单症状疑病性精神病和嫉妒妄想方面特别有效。匹莫齐特在治疗精神分裂症的阴性症状、疼痛综合征和强迫症方面可能也有作用。在回顾支持这些适应症的相关临床文献后,作者们回顾了临床前研究,这些研究为这种独特治疗特性背后的生化机制提供了切入点。